Allspring Global Investments Holdings, LLC Immunovant, Inc. Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$25.1 - $31.61 $104,014 - $130,991	-4,144 Reduced 6.37%	60,947 $1.61 Million
Q1 2024 Apr 18, 2024	BUY	$30.27 - $43.79 $672,781 - $973,276	22,226 Added 51.85%	65,091 $2.1 Million
Q4 2023 Jan 25, 2024	BUY	$31.31 - $44.19 $1.15 Million - $1.62 Million	36,659 Added 590.7%	42,865 $1.81 Million
Q3 2023 Oct 27, 2023	BUY	$18.55 - $39.96 $115,121 - $247,991	6,206 New	6,206 $238,000
Q2 2023 Jul 18, 2023	BUY	$14.2 - $23.75 $38,084 - $63,697	2,682 Added 206.94%	3,978 $75,000
Q1 2023 Apr 13, 2023	SELL	$15.27 - $19.72 $183,041 - $236,383	-11,987 Reduced 90.24%	1,296 $20,000
Q4 2022 Jan 23, 2023	SELL	$6.59 - $17.75 $167,280 - $450,566	-25,384 Reduced 65.65%	13,283 $0
Q3 2022 Oct 26, 2022	SELL	$3.93 - $6.37 $41,241 - $66,846	-10,494 Reduced 21.35%	38,667 $215,000
Q2 2022 Jul 25, 2022	BUY	$3.38 - $5.65 $166,164 - $277,759	49,161 New	49,161 $191,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

Vanguard Group Inc Valley Forge, PA

6.66M
Shares

$183 Million
0.0% of portfolio
Black Rock Inc. New York, NY

4.92M
Shares

$135 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.35M
Shares

$120 Million
4.41% of portfolio
Armistice Capital, LLC New York, NY

3.55M
Shares

$97.6 Million
1.62% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.33M
Shares

$91.6 Million
0.06% of portfolio

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account